Pritelivir Demonstrates Superior Efficacy in People Living with HIV with Refractory HSV in Phase 3 PRIOH-1

Pritelivir Demonstrates Superior Efficacy in People Living with HIV with Refractory HSV in Phase 3 PRIOH-1

Wuppertal, Germany, February 25, 2026 - Aicuris Anti-infective Cures AG (“Aicuris”) today announced superior efficacy results from a subgroup analysis of its pivotal Phase 3 trial (PRIOH-1) evaluating pritelivir vs. investigator’s choice in people living with…

  • In a subgroup analysis of people living with HIV enrolled in PRIOH-1, pritelivir demonstrated superior lesion healing, achieving 61% complete lesion healing compared with 20% receiving invest… [+7429 chars]